CTKB
Cytek Biosciences, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +7.3% ·
net new positions +11.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | 0 | 60.52M | $268.04M | +6 | −6 |
| Q1 2026 | 76 | +1 | 60.92M | $266.22M | +4 | −3 |
| Q4 2025 | 75 | -1 | 61.04M | $308.28M | — | −1 |
| Q3 2025 | 19 | +4 | 43.35M | $150.42M | +4 | — |
| Q2 2025 | 12 | 0 | 36.22M | $123.14M | +1 | −1 |
| Q1 2025 | 9 | 0 | 9.63M | $38.61M | +1 | −1 |
| Q4 2024 | 9 | +1 | 10.70M | $69.47M | +1 | — |
| Q3 2024 | 7 | 0 | 5.47M | $30.29M | — | — |
| Q2 2024 | 7 | — | 6.05M | $33.76M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 4.51M | — | $29.27M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.64M | -1.1% | $17.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.64M | -1.1% | $17.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.52M | -24.4% | $9.85M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Millennium Management ✦ | 803.92K | +321.8% | $5.22M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 462.60K | +118.6% | $3.00M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 389.36K | New | $2.53M | 0.0% | New | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 201.14K | -25.7% | $1.31M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 201.14K | -25.7% | $1.31M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 132.14K | +65.4% | $857,602 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 132.14K | +65.4% | $857,602 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 132.14K | +65.4% | $857,602 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 47.19K | +19.5% | $307,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $2.53M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 164 holders, 84.77M shares, $364.62M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.